Anti-PCSK9 antibodies

US12269897B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Mark Sleeman · New York, US
• Joel H. Martin · Putnam Valley, US
• Tammy T. Huang · Goldens Bridge, US
• Douglas MacDonald · New York, US

Key dates

• Filing date: Apr 5, 2023
• Grant date: Apr 8, 2025
• Expiry date: Apr 5, 2043

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S424/809
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.